Straumann Holding AGXSWX:STMN -1.89%100 Debt-to-EBITDA is 1.45 as of Dec. 2025, which is 101% above its 10-year median of 0.72. GuruFocus rates XSWX:STMN with a GF Score™ of 100/100 and a GF Value™ of CHF137.30 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 468 Medical Devices & Instruments companies, Straumann Holding AG ranks better than 66.45% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Straumann Holding AG's Debt-to-EBITDA or its related term are showing as below:
XSWX:STMN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.52 Med: 0.72 Max: 3.15
Current: 0.67
During the past 13 years, the highest Debt-to-EBITDA Ratio of Straumann Holding AG was 3.15. The lowest was 0.52. And the median was 0.72.
XSWX:STMN's Debt-to-EBITDA is ranked better than 66.45% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 1.555
vs XSWX:STMN: 0.67
Straumann Holding AG (XSWX:STMN) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Straumann Holding AG Debt-to-EBITDA Related Terms
Straumann Holding AG Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Straumann Holding AG's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:STMN vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Straumann Holding AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Straumann Holding AG Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Straumann Holding AG's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Straumann Holding AG's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Straumann Holding AG (XSWX:STMN) has a Debt-to-EBITDA of 1.45 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Straumann Holding AG. This is 101% above median its historical median of 0.72. Over the past decade, Straumann Holding AG's Debt-to-EBITDA has ranged from 0.52 to 3.15. According to the industry distribution chart, Straumann Holding AG ranks #157 out of 468 companies in the Medical Devices & Instruments industry, placing it in the top 33.5%.
Is Straumann Holding AG's Debt-to-EBITDA too high?
Straumann Holding AG's current Debt-to-EBITDA of 1.45 is 101% above median its 10-year median of 0.72. Over the past 10 years, this metric has ranged from a low of 0.52 to a high of 3.15. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.56. Straumann Holding AG's value of 1.45 is 6.8% below this industry median. Based on the distribution chart, Straumann Holding AG ranks #157 out of 468 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Straumann Holding AG has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Straumann Holding AG's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Straumann Holding AG ranks #157 out of 468 companies for Debt-to-EBITDA. This puts Straumann Holding AG in the upper half of its industry. The industry median Debt-to-EBITDA is 1.56. Straumann Holding AG's value of 1.45 is 6.8% below this benchmark. Historically, Straumann Holding AG's own Debt-to-EBITDA has ranged from 0.52 to 3.15 over the past decade. While the company's 10-year median is 0.72 vs. the industry median of 1.56, Straumann Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.56, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Straumann Holding AG's current Debt-to-EBITDA of 1.45 is 6.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Straumann Holding AG. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Straumann Holding AG's current Debt-to-EBITDA is 1.45, which is 101% above median its own 10-year median of 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Straumann Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Straumann Holding AG (XSWX:STMN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF137.30, compared to a current price of CHF106.30 — trading 22.6% below its estimated fair value. The current Debt-to-EBITDA is 1.45, which is 101% above median its 10-year median of 0.72 and 6.8% below the Medical Devices & Instruments industry median of 1.56. Straumann Holding AG's overall GF Score™ is 100/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Straumann Holding AG (XSWX:STMN), the current Debt-to-EBITDA is 1.45 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Straumann Holding AG (XSWX:STMN) Overvalued in 2026?
Based on GuruFocus' analysis, Straumann Holding AG stock appears to be undervalued.
The current stock price of CHF106.30 is trading 22.6% below its estimated GF Value™ of CHF137.30.
GuruFocus considers Straumann Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:STMN:
Debt-to-EBITDA: 1.45 (101% above median its 10-year median of 0.72)
GF Value™: CHF137.30 vs. price of CHF106.30 (22.6% below fair value)
Industry Position: 6.8% below the Medical Devices & Instruments median (#157 of 468)
No single metric tells the full story. See the XSWX:STMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The firm's core products are dental implants, and it holds over one third of the CHF 6 billion global market. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
100GF Score
Get the complete analysis for XSWX:STMN
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:STMN has been successfully added to your 
